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Background: We have developed a new approach to reduce the serum interference for ELISA. The purpose of this
study is to investigate if we can use the optimized ELISA (MBB-ELISA) to detect serum soluble HER2/neu (sHER2) in
early stage primary breast cancer and monitor its change during treatments.
Findings: We collected sera preoperatively from 118 primary breast cancer patients. Serum samples were also
collected sequentially from a subset of patients during and after adjuvant treatment. sHER2 in these samples
was measured by the MBB-ELISA. Only 16.7 % of tissue HER2 (tHER2) positive patients had significantly
elevated sHER2 levels in serum. Interestingly, sera of some patients with tHER2 negative tumors, including
those that were 2+ by IHC but negative by FISH, demonstrated slightly elevated sHER2 levels. Multivariate
analysis demonstrated that patients with elevated sHER2 (> = 7 ng/ml) had significantly worse disease free
survival. During treatments, sHER2 levels consistently fell in response to adjuvant therapies. Nevertheless, in all
4 patients who developed metastases, a steady rise in sHER2 levels was noted before metastatic disease
became clinically evident.
Conclusions: For early stage breast cancers, sHER2 is a poor biomarker to predict tHER2 status, but may have
value to supplement tissue tests to identify patients with HER2 tumors. Our results also suggest that sHER2 is
worth further study as a biomarker to monitor breast cancer patients during treatments.
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Introduction
Currently, women with breast cancer are eligible for
HER2/neu (HER2) based therapy if their tumors express
the HER2 protein, as determined by immunohistochemis-
try (IHC) staining, or if their tumors demonstrate her2/neu
gene amplification, as determined by fluorescence in situ
histochemistry (FISH). In addition to trastuzumab, several
other HER2/neu based targeted therapies are now avail-
able, including pertuzumab and the antibody-drug conju-
gate ado-trastuzumab emtansine (Slamon et al. 2001;
Zhang et al. 2007; Franklin et al. 2004; Cai et al. 2008;
Barok et al. 2011). However, IHC and FISH analyses have
to be performed on tumor tissues, which may not always
be available. In addition, heterogeneous expression of
HER2/neu has been reported in breast cancer at both the* Correspondence: zhanghon@mail.med.upenn.edu
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in any medium, provided the original work is pcellular and tissue level and may result in false negative
HER2/neu expression status (Potts et al. 2012). An alterna-
tive method to ascertain tumor HER2/neu expression sta-
tus that does not rely on tissue sampling would be of value
to guide treatment strategy for patients (Lam et al. 2012).
One such alternative method is to measure serum
levels of the extracellular domain (ECD) portion of the
HER2/neu receptor. During tumor development, tumor
cells shed the ECD of HER2/neu (also known as soluble
HER2, or sHER2) into the circulation (Tse et al. 2012;
Lam et al. 2012) by proteolytic cleavage. ADAM10 was
identified as one of the critical metalloproteinases re-
sponsible for the cleavage of HER2/neu (Liu et al. 2006;
Christianson et al. 1998). The presence of circulating or
soluble HER2 ECD (sHER2) has made it possible to de-
velop serum or plasma-based tests for HER2 (Zhang
et al. 2001; Zhang et al. 2006).
Although FDA-approved tests for sHER2 measurement
are commercially available, these tests are not broadly
used in clinical settings as they are susceptible to highn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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caused by the presence of human anti-animal immunoglu-
bulins (HAIA) in the serum (Papoian 1992). We have de-
veloped a method to eliminate these HAIA using a special
MBB buffer (Zhang et al. 2011). Using this approach, we
studied serum sHER2 by using the mouse antibody mAb
4D5 to capture sHER2 in the sandwich enzyme-linked im-
munosorbent assay (ELISA) (Lam et al. 2014). As the thera-
peutic antibody trastuzumab was derived from mAb 4D5,
this assay can potentially interfere with trastuzumab in the
serum. To circumvent this potential interference, we have
adapted our platform by utilizing a new set of antibodies
that recognizes unique epitopes distinct from trastuzumab,
in order to detect sHER2 from serum samples of both tras-
tuzumab naïve and treated patients (Lam et al. 2012).
In this study, to study the correlation between sHER2
and tissue HER2 (tHER2) status, we first compared tested
sHER2 and tHER2 in 118 patients undergoing primary
breast cancer surgery. Because a subset of these patients
with tHER2 positive disease also had serum samples col-
lected at various time points during and after their adjuvant
therapy, we also sought to determine the changes in sHER2
over the course of adjuvant therapies and whether sHER2
levels were associated with disease progression. Overall, our
results suggest that sHER2 may provide clinical value to
monitor the treatment of patients with Her2+ disease.
Materials and methods
Patients and serum specimens
Under institutional review board (IRB) approved proto-
col, we prospectively enrolled breast cancer patients
undergoing breast cancer surgery at our institution. The
first patient cohort consisted of 118 breast cancer pa-
tients treated at our institution between 2010 and 2014.
Serum samples were collected preoperatively on the day
of their breast cancer surgery after the patients signed
the informed consent form. In a subset of these patients,
serum samples were collected at standardized intervals
during adjuvant treatment.
MBB ELISA for HER2 ECD
Anti-HER2 monoclonal antibodies 6E2 and biotinylated
A21G were used as the capture and detection antibody,
respectively. HER2 ECD standard was originally pur-
chased from Oncogene Sciences. For ELISA, the capture
antibody (6E2, 0.2 μg/ml, 50 μL) was suspended in PBS
and used to coat a 96-well plate by overnight incubation
at 4 °C. After wash with 0.1 % Tween 20 in PBS (PBST),
the plate was blocked with 5% bovine serum albumin
solution in PBS for 1 h at room temperature (22 °C).
HER2 ECD standard and serum samples were diluted in
the Magic Blocking Buffer (MBB) (Zhang et al. 2011)
and incubated for 1-h at 22 °C. Diluted biotinylated
detection antibody (50 μL, 0.5 μg/mL, with MBB) wasadded to each well for a 1 h-incubation at room tem-
perature. Streptavidin-conjugated horseradish peroxidase
(HRP) (R&D systems) was used as the secondary anti-
body to detect the antigen-antibody complex. The plate
was washed three times with PBST in-between incuba-
tions. Following six washes with PBST to remove excess
detection antibodies, 50 μL of tetramethyl benzidine (TMB)
substrate (0.1 mg/mL, 0.05 M phosphate-citrate buffer,
pH 5.0) was added to each well at 22 °C. The reaction was
stopped within 15–30 min with 50 μL of 2 M H2SO4, and
the data was collected at 450 nm (absorbance filter) and
630 nM (reference filter) using the SpectraFluor reader
(Tecan). For comparison, a commercial sHER2 detection
kit from Wilex (Wilex/oncogene Science, Cambridge, Mass)
was used, and the test was performed according to the rec-
ommended procedure.
Statistical analyses
Demographics and clinical characteristics including race,
age at diagnosis (defined as the date of initial breast cancer
surgery), tumor subtypes according to receptor status,
tumor size (as continuous variable or as categorical vari-
able by Tumor Node Metastasis (TNM) classification),
number of involved or (+) axillary lymph nodes (as ordinal
or as categorical variable by TNM classification), and
types of adjuvant systemic therapy (if applicable) were col-
lected by detailed chart review. Tumor receptor subtypes
were classified into three groups: Group 1 was comprised
of ER+ breast cancer which expressed either ER or PR and
lacks HER2 expression; Group 2 was comprised of HER2+
breast cancer which expressed HER2 as determined by
IHC and/or FISH with or without expression of ER or PR;
and Group 3 was comprised of TNBC which lacked ex-
pression of ER, PR, and HER2. Clinical characteristics and
sHER2 measurements were compared across the three
groups using either a two-tailed student’s t-test for con-
tinuous covariates (i.e., age and tumor size) or a two-tailed
Fisher’s Exact Test for discrete or ordinal covariates (i.e.,
histologic types, and number of (+) axillary lymph nodes
(0 vs. ≥ 1). Univariate and multivariate analyses were per-
formed to assess both overall and disease-free survival out-
comes using Kaplan-Meier analyses and Cox-proportional
hazards models.
Result
Concordance between MBB HER2 ELISA and the
commercial Wilex HER2/neu ELISA assay
Using human HER2-expressing murine cell line T6-17,
we have developed several anti-HER2 antibodies (Zhang
et al. 2006). Two antibodies, 6E2 and A21G, were selected
as a pair of antibodies for the sHER2 ELISA. Using this
pair of antibodies and also the MBB buffer (Zhang et al.
2011), we assembled the MBB HER2 ELISA assay to de-
tect sHER2 in serum from patients. Previously, we have
Fig. 1 Correlation between MBB assay and the commercial Wilex
assay for serum sHER. Forty serum samples were grouped into either
tHER2 negative (blue diamond) or positive (red triangle) and tested
by both assays. Both groups showed good correlation of sHER2
levels between these two assays
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ence and thus eliminated false positive in control samples
(Zhang et al. 2011). A critical question to address was
whether the MBB affected the readouts for true positive
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Fisher’s test. N/A: in 1 patient, relevant information (e.g., tumor size) was missingcommercially available Wilex HER2/neu assay (Nuclea
Diagnostic, Cambridge, MA) was thus planned using a
subset samples (n = 40) from our cohort.
As showed in Fig. 1, sHER2 levels as measured by the
two methods showed very similar values. The overall
correlation (R2) for all samples tested was 0.96307.
When samples were grouped according to tissue HER2
(tHER2) status, the two assays appeared to have better
correlation in tHER2+ samples (R2 0.93952 vs 0.6127 in
tHER2-). The weaker correlation in tHER2− samples was
likely due to the variability in sHER2 readouts when the
target protein was at low abundance. Both assays re-
vealed that tHER2 positive patients could have normal
levels of sHER2.
Correlation of serum levels with tissue HER2 status
As results of breast cancer serum samples using our
own MBB sHER2 assay were comparable to those ob-
tained using the commercially available Wilex assay, we
proceeded to use our MBB assay to measure sHER for
the rest of our study. The mean sHER2 values and corre-
sponding clinical and tumor characteristics of our study
cohort were summarized in Table 1. No significant cor-
relation was noted between sHER2 with age at diagnosis,
tumor size, or axilla lymph nodes status. sHER2 levelsN sHer2 values p values a





















an epidermal growth factor receptor 2. aThis P value was determined using the
Fig. 2 Elevated sHER2 levels in tissue HER2 positive patients (tHER2+).
sHER2 levels were determined by MBB ELISA. tHER2+ patients had
significantly higher average sHER2 levels
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races, receptor subtypes or disease status (p-values of
0.04, 0.032 and 0.007, respectively). Interestingly, patients
noted to be of Asian descent had significantly higher
sHER2 levels compared to those of other ethnicities. As
expected, sHER2 levels were significantly higher in tHER2+
subtype compared to tHER2− or TNBC subtypes. The
sHER2 levels of tHER2+ patients ranged from 2.2 to
29.2 ng/ml with a mean of 8.3 ng/ml while the sHER2
levels in tHER2− patients ranged from 0 to 10.4 ng/ml withFig. 3 Disease free survival of breast cancer patients after surgery. Kaplan-M
adverse patient outcome in two cohorts using recurrence-free survival as ca mean of 5.1 ± 2.2 ng/ml (Fig 2, p < 0.0001). While all of
tHER2− patients had relatively low levels of sHER2, it was
also evident that only a small fraction of tHER2+ patients
(n = 3) had dramatically elevated serum levels (>15 ng/ml,
Fig. 2). Of the 23 patients with tHER2+ tumor, 45.8 % had
elevated sHER2 levels (> = 7 ng/ml), as defined by sHER2
’values greater than the 75th percentile, while only 16.7 %
(n = 16) of tHER2− patients had elevated sHER2 levels
(range: 7.0–10.6 ng/ml). Three of these patients were FISH
negative but had an IHC score of 2+, indicating a likelihood
of HER2 protein overexpression even in the absence of
gene amplification.
sHER2 levels may have prognostic significance: higher
sHER2 levels correlates with worse clinical outcomes
Over a median follow-up of 19 months, we observed dis-
ease recurrence in 12 patients (10 %) (Table 1). Patients
who developed disease recurrence had significantly
higher baseline sHER2 levels than those who remained
disease-free (8.5 vs. 5.4 ng/ml, p = 0.007, Table 1). To
further evaluate if baseline (preoperative) sHER2 corre-
lated with clinical outcomes, Cox analysis was per-
formed to compare patients with sHER2 in the 75th
percentile (≥7 ng/ml) and those with lower sHER2
(<7 ng/ml). Univariate analysis demonstrated that sHER2
levels were significantly associated with disease-free sur-
vival (log-rank score test: p = 0.009, hazard ratio HR =
1.117 +/− 0.044). In multivariate analysis, sHER2 levels
remained independently associated with disease-free
survival. We further performed Kaplan-Meier analysis
(Fig. 3). Disease-free survival was significantly worse ineier analyses showing the association of preoperative sHER2 with
linical endpoints
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score test, p = 0.0098).
Serial sHER2 levels to assess disease progression
In a subset of patients (n = 16), serum samples were col-
lected at various time points during and after adjuvant
therapy. Of these 16 patients, four developed disease re-
currence. Their serial sHER2 levels over the follow-up
period were examined and grafted with their treatment
and disease status (Fig. 4). In one patient (#10048), we
noted that sHER2 level was significantly reduced after
mastectomy. In general, we observed a steady rise in
sHER2 levels before distant metastases became clinicallyFig. 4 Monitoring sHER2 levels in 4 patients who eventually developed rec
periodically and tested using MBB-HER2 ELISA. Treatments and recurrence
adjuvant therapies and had a local recurrence. After bilateral mastectomy, s
Herceptin treatments. Brain metastasis was identified during the sHER2 risin
Patient#10048 showed a drop of sHER2 after chemo/Herceptin treatments
sHER2 gradually went up after local recurrence was identified. The patient
sHER2 kept surging. Eventually the navelbine/Herceptin combination was a
sHER2 responded to the initial chemo/Herceptin treatment and dropped to
alone treatment. After radiation, the level was reduced again to a very low
was identified. d sHER2 levels in #10061 was restricted in a very narrow ran
radiation, sHER2 gradually bottomed out at 2 ng/ml. In less than 2 months, sH
was detected. Serum samples right before metastasis was not available and it
Treatments: A: Adriamycin; Cy: Cytoxan; T: Taxol; H: Herceptin; X: Xeloda; Ha: Hevident in three of the four patients who developed dis-
ease recurrence (patient 10004, 10041 and 10061).
Discussions
Correlation of sHER2 and tHER2 status – sHER2 is not a
useful predictive marker for tHER2 positive status in
primary breast cancer patients
The ability to measure sHER2 as a non-invasive means to
monitor tumor HER2 status has generated much interest
in the past 20 years (Colomer et al. 2000; Esteva et al.
2005). Although the sHER2 test has failed to prevail as a
standard clinical screening test to determine eligibility of
HER2 targeted therapies, many studies have shown theurred diseases. Serum samples of these patients were collected
/ metastasis were indicated. a Patient#10004 failed to respond to
HER steadily went up, even in the presence of radiation and additional
g phase, and eventually the patient developed liver metastasis. b
and mastectomy. After about 2 months of staying at the bottom,
was treated with several kinds of chemotherapies with Herceptin, but
ble to change the course of rising sHER2 levels. c In patient #10041,
< 2 ng/ml. The level rebounded to ~ 4 ng/ml during the Herceptin
level (<1 ng/ml). However, sHER2 level rose again and brain metastasis
ge over the course of treatment. After bilateral mastectomy and
ER2 rose from 2 ng/ml to 4 ng/ml. Two months later, brain metastasis
is not clear if the upward trend of sHER2 continued until brain metastasis.
alaven; L: Lapatinib; Na: Navelbine; Rad: radiation
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ease stages, and disease free survival (Ludovini et al.
2008). As noted above, one of the major limitations in the
serum ELISA assay is the serum interference associated
with human anti-animal antibodies that leads to mostly
false positive results (Lam et al. 2012). To circumvent this
problem, we have developed a unique MBB blocking
buffer as described in our earlier studies (Zhang et al.
2011; Lam et al. 2014). In this study, we further evaluated
the association between tHER2 and preoperative sHER2
values in a prospective study cohort using our MBB
sHER2 assay. We found that only 16.7% of tHER2 positive
early stage breast cancer patients had dramatically ele-
vated sHER2 levels.
Our results are similar to those from larger clinical tri-
als involving early stage primary breast cancer patients.
In one study, only 12 % of 2318 tHER2 positive patients
had elevated preoperative sHER2 levels (Moreno-Aspitia
et al. 2013). In another recent study of 2862 cases of
stage I–III primary breast cancer patients, 24 % were
found to be tHER2 positive, and only 15 % of these tis-
sue positive patients had elevated sHER2 (Lee et al.
2014). Therefore, sHER2 is a poor diagnostic marker for
early stage breast cancer and should not be used to re-
place conventional IHC or FISH analyses to guide treat-
ment planning.
sHER2 levels correlates with disease status-possible role
of sHER2 as a non-invasive biomarker to monitor disease
progression during or after adjuvant therapy
In a previous study when we examined a cohort of inva-
sive breast cancer patients that included late stage meta-
static cases, elevated sHER2 levels were detected in
about 32% of samples, suggesting that sHER2 may be
more closely associated with tHER2 positivity in patients
with heavier tumor burden or with metastatic disease
(Lam et al. 2014). Furthermore, we have previously mon-
itored sHER2 in 12 patients with DCIS who had received
dendritic cell-based vaccines against HER2 peptide prior
to their definitive surgery (Lam et al. 2014). In one of
these 12 patients, sHER2 continued to rise. Metastatic
tHER2 positive disease was subsequently diagnosed in
this patient. Results from our sequential measurement of
sHER2 in patients during and after adjuvant therapy also
demonstrated that sHER2 levels would rise in patients
who subsequently developed clinically evident distant
metastases. Taken together, sHER2 monitoring may be
useful in monitoring disease progression.
Future directions
A key question remains to be addressed is whether the
sHER2 assay can be used in supplement to IHC/FISH to
identify patients who have modestly elevated sHER2 and
be responsive to HER2 targeted therapies. This will behelped by the determination of the range of sHER2 value
in healthy people by our assay. As we have overcome the
initial hurdle for measuring sHER2 due to interference
in serum that caused false positive even in normal
serum, the normal sHER2 values by our assay could be
lower. A study with healthy volunteer serum samples
has been planned. In addition, as a high sHER2 pre-
operative value predicts worse prognosis, sHER2 may be
used to further stratify and identify patients who may
benefit from newer targeted therapies in future studies.
More work is also needed to validate the best clinical
use for this assay such as to monitor disease progression
for those with high risk tHER2 positive disease.
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